Akebia Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
State Street Corporation has reported beneficial ownership of 4.3% of Akebia Therapeutics Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group reported a 0% beneficial ownership in Akebia Therapeutics Inc. following an internal realignment.
NASDAQ
State Street Corporation has reported a 5.2% beneficial ownership stake in Akebia Therapeutics Inc., holding 13,687,561 common shares as of December 31, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.2% beneficial ownership stake in Akebia Therapeutics Inc., totaling 19,219,819 common shares.
NASDAQ
The Vanguard Group has reported a 5.37% beneficial ownership stake in Akebia Therapeutics Inc., holding 12,685,803 common shares as of March 31, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.1% passive ownership stake in Akebia Therapeutics Inc. as of March 31, 2025.
NASDAQ
Muneer A. Satter has filed an amended Schedule 13G, reporting a 2.6% passive beneficial ownership stake in Akebia Therapeutics, Inc. as of December 31, 2024.